# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...
Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $26 to...
https://clinicaltrials.gov/study/NCT06328777 Inclusion Criteria:
Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $...
HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target fr...
- SEC Filing
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.3...